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Background
Patients with end‑stagerenal disease (ESRD) on regular hemodialysis (HD) show various
otolaryngological manifestations owing to uremic toxins and electrolyte imbalance. Previous
studies have reported epistaxis as the most common ENT manifestations of ESRD on HD
as explained by bleeding tendency related to uremia or HD itself. Nasal crustation, septal
perforation, and olfactory dysfunction were also observed in HD patients.

Objective

To evaluate the frequency of different nasal manifestations among nondiabetic prevalent HD
patients.

Patients and methods

A cross‑sectional study was conducted in Ain Shams University Hospital from March 2019 till
September 2019. It included 68 eligible nondiabetic patients with ESRD on regular HD more
than 6 m. All patients were subjected to full history and clinical examination. CT nose and
sinus was done only if indicated. Complete blood count and routine chemistry (blood urea
nitrogen, serum creatinine, urea reduction ratio, calcium, phosphorus, parathyroid hormone,
and iron profile) were done.

Results

Most patients did not give a past history of epistaxis (94.1%). Overall, 44.1% of the patients
experienced dry nasal mucosa and pale inferior turbinates, and 10.3% of the patients had
congested nasal mucosa. Crustations were founded in 7.4% of the patients, although they were
found in nearly double percentage in nasal septum (14.7%). The nasal septum deviation and
ulceration were found in 2.9% each. Only one (1.5%) patient had nasal septum perforation.
The mean level of hemoglobin (g/dl) concentration was 10.4 (range, 6.8–15 g/dl).

Conclusion

Modern adequate HD techniques have reduced epistaxis in patients with ESRD. The most
common ENT manifestations were dry nasal mucosa and pale inferior nasal turbinate and to
a lesser extent crustations on both nasal septum and inferior nasal turbinate.
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Introduction
Chronic renal insufficiency affects hemostasis
by multiple pathways, resulting either in an
anticoagulatory state characterized by bleeding
episodes or in a procoagulatory state characterized by
frequent thrombosis [1].
Bleeding disorders are due to inadequate platelet
function, coagulation cascade, and/or activation of
fibrinolytic system, whereas hypercoagulability is
the product of regulatory coagulation disorders and
hyperactivity of platelets [2].
Increased bleeding tendency in patients with renal
failure may present clinically as gastrointestinal
bleeding, retinal hemorrhage, subdural hematoma,
epistaxis, hematuria, ecchymosis, purpura, bleeding
from the gums, gingival bleeding, genital bleeding,
hemoptysis, telangiectasia, hemarthrosis, and
petechiae [3].

Interestingly, hemodialysis (HD) itself may predispose
to bleeding disorders, not only because of the heparin
administered but also because of continuous platelet
activation at the dialyzer membrane with following
decreased dialyzer activity [4]. On the contrary, HD
has been shown to reduce platelet disorders, leading
to decreased risk of bleeding because of uremic toxin
removal [5].
In patients with renal failure, anemia directly affects the
bleeding time [6,7]. Erythrocytes lead to accumulation
of platelets along the vessel walls within the blood
stream together with stimulating the release of platelet
ADP and an inactivation of PGI2, thus activating
platelet function [8].
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Nasal septal perforation in uremic patients may occur
owing to trauma from nasal catheters and impaired
proliferation of mucosal cell. Moreover, disturbed
innervation of the vessels in the nasal septum owing to
autonomous nervous system neuropathy and ischemia
secondary to arteriolar narrowing may play a role [9].
Infection is common among patients with end‑stage
renal disease (ESRD) undergoing HD, leading to
hospitalization, with high rate of morbidity and
mortality. The most frequently involved microorganism
is Staphylococcus aureus, which is the most common
endogenous organism in the anterior nares [10].
Autonomic dysfunction is highly encountered in
chronic renal failure (CRF) and occurs in HD patients
in a percentage that reaches ∼50%. Autonomic outflow
is disturbed, leading to sympathetic overdrive and
declining parasympathetic activity. This sympathetic
overdrive is potentially mediated by renal sensory
afferents in damaged kidneys and is potentiated by
impaired chemo sensory function, elevated circulating
humoral and metabolic factors such as angiotensin II,
and cardiovascular remodeling [11].
Olfaction may deteriorate in case of end‑stage renal
failure owing to malnutrition and impaired fluid
intake [12]. Uremic neuropathy usually occurs owing
to accumulation of uric acid, indoxyl sulfate, p‑cresyl
sulfate, interleukin 1 beta, interleukin 6, tumor necrosis
factor‑alpha, and parathormone, resulting in myelin
sheath injury and axonal degeneration. Olfactory
neuropathy may occur owing to uremia in patients
with CRF [13,14].

Patients and methods
This cross‑sectional study was conducted over a
6‑month duration to evaluate the frequency of nasal
affection among 68 prevalent HD patients in Ain
Shams University Hospital. Eligibility criteria were
age more than or equal to 18 years, patients were
scheduled on regular thrice‑weekly 4 h sessions of
conventional HD, and adequate HD sessions more
than 6 months before the study with a standard
bicarbonate‑containing dialysate, using biocompatible
HD polysulfone low‑flux dialyzer and heparin as
anticoagulant. We excluded any patients who had
diabetes mellitus, active autoimmune disease, advanced
liver disease, or malignancy. Moreover, patients with
previous nasal or sinus diseases were excluded.
All patients were subjected to full history and clinical
examination with emphasis on demographic features,
smoking, the etiology of renal failure, dialysis duration,

vascular access, drug history, history of any diagnosed
hereditary or acquired comorbidities, BMI, and blood
pressure. ENT examination included close observation
of any external nasal swellings, deformities, nasal
versus mouth breathing, color of nasal mucosa,
edema, hypertrophy, polyps, granulations, deviated
or perforated nasal septum, discharge, or bleeding.
Computed tomography (CT) nose and sinus was done
only if indicated, as in patients with epistaxis, nasal
obstruction, and recurrent sinusitis.
Laboratory
investigations
included
blood
hemoglobin level, blood urea nitrogen, serum
creatinine,
calcium,
phosphorus,
parathyroid
hormone, iron study, and CRP titer. Urea reduction
ratio=(U pre–U post)/U pre × 100%) (U pre is the
predialysis urea level and U post is the postdialysis urea
level) and Kt/V (K: dialyzer clearance, t: duration of
dialysis, V: volume of bodily water) were measured to
assess the adequacy of dialysis.
Statistical analysis

Statistical analysis of data was done by IBM computer
using SPSS (Statistical Program for the Social Sciences,
version 18, IBM SPSS USA). Quantitative data were
presented as range, mean, and SD. Qualitative data
were presented as number and percent. χ2 test was
used to compare qualitative variables between groups.
Student t test was used to compare quantitative
variables between two groups. One‑way analysis of
variance test was used to compare quantitative variables
between more than two groups. P value less than 0.05
was considered significant.
Ethical considerations: all procedures performed in
the study were in accordance with ethical standards of
Ain Shams University Hospital Research Committee
and with the ethical standards laid down in the
1964 Declaration of Helsinki. This study was approved
by our institutional review board, and informed
consent was obtained from all individuals enrolled in
the study.

Results
A
total
of
68
eligible
HD
patients
(35 males and 33 females), with a mean age
of 52.1 ± 13.3 year and mean HD duration of
7.9 ± 5.58 years were included. The causes of renal
failure were hypertension in 21 (30.9%) patients,
chronic pyelonephritis in 11 (16.17%), amyloidosis in
two (2.9%), analgesic nephropathy in seven (10.3%),
lupus nephritis in two (2.9%), chronic obstructive
uropathy in seven (10.3%), polycystic kidney in
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three (4.4%), and 15 (22.1%) patients of unknown
etiology. Associated risk factors noticed in our
studied patients are as follows: 16.2% of patients
were smokers, 22 (32.4%) patients were hypertensive,
and 26 (38.2%) patients with seropositive HCV. The
parameters of adequacy of HD were the mean urea
reduction ratio of 66.63 ± 10.21% and mean Kt/V
of 1.37 ± 0.26 were parameters of adequacy of HD.
Regarding medications, calcium dose (mg/day) had
a mean of 2363.2 ± 950.3, the mean of vitamin D
dose (µg/week) was 0.92 ± 1.02, and the mean of
erythropoietin dose (IU/kg/week) was 53.4 ± 35.47.
Demographic and clinical data are shown in Table 1
and laboratory results are shown in Table 2.
Nasal mucosa was normal in 45.6% of patients,
whereas 44.1% of the patients experienced dry
nasal mucosa. Only 10.3% of the patients had
congested nasal mucosa. Inferior nasal turbinates
in most of our patients (44.1%) were pale, whereas
were normal in 35.3% and were hypertrophied
in 13.2%. Crustations were found only in 7.4% of
patients in the inferior turbinates, although they
were found in nearly the double percentage in nasal
septum (14.7%) (Table 3).
Most studied patients (77.9%) had normal nasal
septum, whereas the most significant finding observed
was nasal septum crustations in ∼14.7% of patients
and to a lesser extent the nasal septum deviation and
ulceration, with 2.9% each. Only one (1.5%) patient
had nasal septum perforation (Table 3).
Most patients did not give past history of
epistaxis (94.1%). Mean hemoglobin level in patient
with no evident epistaxis was 10.5 ± 1.7 g/dl versus
9.2 ± 1.6 g/dl in patients with epistaxis, with P value
more than 0.05. Correlation between epistaxis and all
parameters was statistically nonsignificant, except for
sex, as none of our male patients experienced epistaxis
during our study (P = 0.034) (Table 4).
Logistic regression analysis, after applying the forward
method and entering some predictor variables such
as the increase in disease duration, HD duration,
smoking, and ferritin, shows an independent effect
on increasing the probability of nasal mucosa
abnormalities occurrence, with significant statistical
difference (P < 0.05 each).
Logistic regression analysis, after applying the forward
method and entering some predictor variables such
as the decrease in transferrin saturation and albumin,
shows an independent effect on increasing the
probability of epistaxis occurrence, with significant
statistical difference (P < 0.01 each).
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Table 1 Demographic and clinical data among the studied
hemodialysis patients
Variables
Age (years)
Dry weight (kg)
BMI
MAP (mmHg)
Hemodialysis duration (year)
Sex
Female
Male
Smoking
Nonsmoker
Smoker
Hypertension

Mean±SD/n (%)
52.1±13.3*
67.27±16.2
26.25±4.8
93.7±16.7
7.9±5.58
33 (48.5)
35 (51.5)
57 (83.8)
11 (16.2)
22 (32.4)

HCV seropositive

26 (38.2)

Table 2 Laboratory data among hemodialysis patients (n=68)
Mean±SD
Urea reduction ratio (%)
Calcium (mg/dl)
Phosphorus (mg/dl)
Parathyroid hormone (ng/l)
TSAT (%)
TIBC (µg/dl)
Ferritin (ng/ml)
Iron (µg/dl)
HB (gm/dl)
Albumin (g/dl)

66.63±10.21
11.0±13.07
4.33±5.19
465.4±407.1
41.37±19.89
197.3±45.81
1737.0±541.1
95.96±106.8
10.28±2.02
3.65±0.45

Creatinine (mg/dl)

2.68±0.77

Hb, hemoglobin; TIBC, total iron‑binding capacity; TSAT, transferrin
saturation.
Table 3 Nasal manifestations among nondiabetic
hemodialysis patients (n=68)
n (%)
Nasal septum
Normal
Crustation
Deviation
Ulceration
Perforation
Nasal mucosa
Normal
Dryness
Congestion
Turbinate
Normal
Pale
Crustation
Hypertrophy
Epistaxis (history)
Negative
Positive

53
10
2
2
1

(77.9)
(14.7)
(2.9)
(2.9)
(1.5)

31 (45.6)
30 (44.1)
7 (10.3)
24 (35.3)
30 (44.1)
5 (7.4)
9 (13.2)
64 (94.1)
4 (5.9)

Discussion
Uremic patients display a bleeding diathesis that is
primarily due to hemostasis abnormalities, particularly
platelet dysfunction and impaired platelet‑vessel
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Table 4 Correlation between epistaxis and other parameters
Epistaxis [n (%)]
Sex
Female
Male
Smoking
Nonsmoker
Smoker
Etiology HTN
No
Yes
Duration of CRF (years)
0‑5

χ2

P

Significance

Negative

Positive

29 (45.3)
35 (54.7)

4 (100.0)
0

4.508(b)

0.034

S

55 (85.9)
9 (14.1)

2 (50.0)
2 (50.0)

3.586(b)

0.058

NS

45 (70.3)
19 (29.7)

1 (25.0)
3 (75.0)

3.532(b)

0.060

NS

25
14
12
10
3

(39.1)
(21.9)
(18.8)
(15.6)
(4.7)

2 (50.0)
2 (50.0)
0
0
0

2.942

0.568

NS

51 (79.7)
8 (12.5)
2 (3.1)
2 (3.1)
1 (1.6)

2 (50.0)
2 (50.0)
0
0
0

4.338

0.362

NS

11‑15
16‑20
21‑25
Nasal septum
Normal
Crustation
Deviation
Ulceration
Perforation
Nasal mucosa
Normal
Dryness
Congestion
Turbinate
Normal
Pale
Crustation

31 (48.4)
26 (40.6)
7 (10.9)

0
4 (100.0)
0

5.383

0.068

NS

24 (37.5)
26 (40.6)
5 (7.8)

0
4 (100.0)
0

5.383

0.146

NS

Hypertrophy

9 (14.1)

0

CRF, chronic renal failure; S, significant.

wall interaction. These patients, however, have a
high prevalence of cardiovascular and thrombotic
complications, despite the reduced platelet function [2].

reduced risk of bleeding [5]. These results may match
our finding, as only 5.9% of our patients experienced
epistaxis.

Bleeding has been reported in 40–50% of patients with
CRF or on HD [3]. A hospital‑based study showed
that the risk of attacks of bleeding increased twice in
patients with renal failure [4].

Patients with advanced renal failure may show clinical
manifestations that affect both the hard and soft tissues.
Occasionally, these manifestations may be owing to
therapeutic measures that include the following: fluid
restrictions; dietary changes; adverse effects of some
medications; including antihypertensives, painkillers,
diuretics, antidepressants, and anti‑inflammatory
drugs, which are commonly used in these patients; and
dialysis and/or kidney transplantation patients [18].
One of these mucosal manifestations is dryness.
Sadeghdehghanmehr et al.[19] found that the mean
occurrence of dry mouth is seen in ∼44.02% of their
patients. Dry mouth in HD occurs owing to a variety
of causes, such as limited intake of fluids at intervals
between two dialysis [20]. In this study, we observed
that the most common nasal manifestations in patients
with CRF on regular dialysis are dry nasal mucosa and
pale inferior nasal turbinates (44.1% each).

Di Minno et al.[15] reported prolonged bleeding
time to be more than 8 min in their study and
explained this by abnormal platelet aggregation and
thromboxane B2 formation and mentioned that these
changes are corrected partially following dialysis.
Kumar et al. [16], mentioned that the most common
ENT manifestation of patients with CRF on dialysis
is epistaxis, representing about 30%, and in most of
these patients, epistaxis was arrested, immediately
after correction of blood urea. Bleeding tendency
can be reduced by using modern dialysis techniques
and the use of erythropoietin to correct anemia [17].
Moreover, removal of uremic toxins after HD has been
shown to improve platelet abnormalities, resulting in a
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Mucociliary activity of the respiratory mucosal surfaces
greatly affects its ability to eliminate foreign particles and
pathogens and to keep mucosal surfaces moist and fresh.
CRF and HD cause severe prolongation of mucociliary
clearance time as reported by Sinan et al. [21].
In addition, Fan and Baiya [10], identified endogenous
gram‑positive cocci infection, in particular S. aureus, as
the most common cause of hospitalization, morbidity,
and mortality among patients with ESRD undergoing
HD. The anterior nares are the most common
endogenous SA carrier sites.
Nasal irrigation can activate the ciliary motility and
decrease the bacterial adhesion, leading to increase in
mucociliary clearance and decrease in mucous membrane
inflammations, through flushing away inflammatory
mediators, the crust, and other nasal discharges [22].
The second common nasal manifestation found in
this study is the nasal septum crustations (14.7%), and
then hypertrophied inferior nasal turbinates (13.2%),
followed by congested nasal mucosa (10.3%).
Crustations were founded in 7.4% of the inferior
nasal turbinates of our patients, and nasal septal
ulceration was found in 2.9%. These results may be
explained by the study done by Kumar et al. [16], who
mentioned that the high urea level with an average of
320 mg/100 ml, which was excreted in nasal secretions,
is splitted by nasal bacteria, releasing ammonia,
which leads to chemical rhinitis, the possible cause
of congestion, ulceration of nose, and submucosal
hemorrhages. In most of their patients, the lining of
the mucous membrane returned to normal in 3–5 days
after dialysis.
Nasal septal perforation was observed in only one
patient in this study (1.5%). However, Adler and Ritz[9]
reported spontaneous perforation of the nasal septum
in eight (8.32%) of 104 patients and contributed this to
local trauma after nasal catheterization postoperatively,
impaired proliferation of mucosal cell, and autonomic
neuropathy owing to disturbed innervation of the
vessel wall in the nasal septum.
Although olfactory neuropathy was reported in patients
with CRF [13,14] and the hypothesis of elevated odor
thresholds was studied by Frasnelli et al. [12], who
mentioned that 56% of the CRF patients were found
to be anosmic or hyposmic, we did not observe such
manifestation in our study.

Conclusions
The most common ENT manifestations were dry
nasal mucosa and pale inferior nasal turbinates and to
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a lesser extent crustations on both nasal septum and
inferior nasal turbinates. The incidence of epistaxis has
been reduced in patients with ESRD on regular HD.
Nasal septal ulceration and perforation are the least
common ENT manifestation. No cases with olfactory
neuropathy were reported in our study.
Recommendations

(1) Patients with CRF on HD should keep their nasal
mucosa wet using regular saline irrigation and
moisturizing agents such as gel and ointments.
(2) Correction of anemia and regular HD helps in
decreasing bleeding tendency in uremic patients.
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